Company Encyclopedia
View More
name
Galapagos NV
GLPG.US
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
1.946 T
GLPG.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking200/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-16.72%E
    • Profit Margin-151.94%E
    • Gross Margin-19.07%E
  • Growth ScoreC
    • Revenue YoY12.78%B
    • Net Profit YoY-316.00%E
    • Total Assets YoY-11.59%E
    • Net Assets YoY-10.22%D
  • Cash ScoreC
    • Cash Flow Margin-65.81%D
    • OCF YoY12.78%B
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreB
    • Gearing Ratio30.32%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Galapagos NV (NASDAQ:GLPG) Given Consensus Rating of "Reduce" by Analysts

    Galapagos NV (NASDAQ:GLPG) has received an average recommendation of "Reduce" from nine research firms, with five analysts rating it as a sell, two as hold, one as buy, and one as strong buy. The average twelve-month price target is $31.33. Recent analyst ratings include outperform, hold, sell, and strong-buy. Institutional investors own 32.46% of the stock. The company's stock is currently trading at $31.77.

    Market Beat·
    US
    GLPG
    0.00%
    Market Beat·
    US
    GLPG
    0.00%

    Galapagos Receives Transparency Notifications from Bank of America

    Mechelen, Belgium. November 26, 2025, 07:30 CET. regulated information - Galapagos NV ( Euronext & NASDAQ: GLPG ) received transparency notifications from Bank of America.

    GlobeNewswire·
    US
    GLPG
    0.00%
    GlobeNewswire·
    US
    GLPG
    0.00%

    Galapagos CEO tightens strategic focus in pursuit of key assets

    Galapagos CEO Henry Gosebruch is focusing on strategic asset acquisitions following the shutdown of the cell therapy unit. With a €3bn balance sheet, the company aims to create a profitable business model by targeting late-stage assets in immunology and oncology. The recent surge in M&A activity is seen as beneficial for Galapagos, aligning with industry trends of targeting later-stage assets. The company is moving away from cell therapy due to logistical challenges and is seeking sustainable business opportunities.

    Pharmaceutical Technology·
    US
    GLPG
    0.00%
    Pharmaceutical Technology·
    US
    GLPG
    0.00%

    Barclays Keeps Their Sell Rating on Galapagos (0JXZ)

    Barclays analyst Shirley Chen has maintained a Sell rating on Galapagos (0JXZ) with a price target of €22.00. The current analyst consensus on Galapagos is a Strong Sell, with an average price target of €22.75. Chen specializes in the Healthcare sector and has an average return of 3.2% with a 59.09% success rate on stock recommendations.

    Tip Ranks·
    US
    GLPG
    0.00%
    Tip Ranks·
    US
    GLPG
    0.00%

    Galapagos (0JXZ) Receives a Sell from Bank of America Securities

    Bank of America Securities analyst Jason Gerberry has maintained a Sell rating on Galapagos (0JXZ), with shares closing at €26.84. The analyst consensus is a Moderate Sell, with an average price target of €23.50, indicating a potential downside of 12.44%. Kepler Capital also reiterated a Sell rating with the same price target. Gerberry, a 5-star analyst, has an average return of 10.6% and a 58.23% success rate, covering the Healthcare sector.

    Tip Ranks·
    US
    GLPG
    0.00%
    Tip Ranks·
    US
    GLPG
    0.00%
    © 2025 Longbridge｜Disclaimer